Compare Davita Inc (DVA) vs iShares JPMorgan USD Emerging Markets Bond ETF (EMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs iShares JPMorgan USD Emerging Markets Bond ETF — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.59 (market cap $12.79B). The key difference: Davita Inc and iShares JPMorgan USD Emerging Markets Bond ETF are close in size by market cap, and Davita Inc is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and iShares JPMorgan USD Emerging Markets Bond ETF for 50 Days on average.
| DVA | EMB | |
|---|---|---|
Market Cap | $11.28B | $12.79B |
Volume | 650,294 | 8,552,536 |
Sector | Health | Fixed Income |
52-Week High | $240.96 | $97.74 |
52-Week Low | $103.87 | $90.14 |
Typical Hold Time | 113 Days | 50 Days |
Enterprise Value | $24.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
EMB trades at $90.78, down 0.19% with a bearish technical signal from moving averages. The stock shows mixed momentum with RSI indicators suggesting potential oversold conditions at lower timeframes. Recent corporate actions include scheduled dividend payments through late 2026, though key valuation and profitability metrics remain unavailable for analysis.
The outlook remains cautious with technical indicators favoring bearish momentum. Investment appeal may center on future dividend income given the lack of current fundamental data. Primary risks include market volatility and the absence of transparent financial metrics for proper valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →
